Increased @entity5 mortality following a history of XXXX .

@entity1 @entity5 @entity1489 @entity167 @entity1778 @entity1893 @entity320
CONTEXT: Cancer registries have reported an increased incidence of @entity320 and certain noncutaneous @entity5 following @entity1489 ( @entity1489 ). Whether these findings were attributable to intensified surveillance, shared risk factors, or increased @entity5 susceptibility remains unclear. OBJECTIVE: To determine whether a history of @entity1489 predicts @entity5 mortality. DESIGN: Prospective cohort with 12-year mortality follow-up adjusted for multiple risk factors. SETTING: Cancer Prevention Study II, United States and Puerto Rico. @entity1 : Nearly 1.1 million adult volunteers who completed a baseline questionnaire in 1982. MAIN OUTCOME MEASURE: Deaths due to all @entity5 and common @entity5 . RESULTS: After adjusting for age, race, education, smoking, obesity, @entity167 use, and other conventional risk factors, a baseline history of @entity1489 was associated with increased total @entity5 mortality ( @entity1 's relative risk [RR], 1.30; 95% confidence interval [CI], 1.23-1.36; @entity1 's RR, 1.26; 95% CI, 1.17-1.35). Exclusion of deaths due to @entity320 reduced these RRs only slightly. Mortality was increased for the following @entity5 : @entity320 (RR, 3.36 in @entity1 , 3.52 in @entity1 ); pharynx (RR, 2.77 in @entity1 , 2.81 in @entity1 ); lung (RR, 1.37 in @entity1 , 1.46 in @entity1 ); @entity1893 (RR, 1.32 in @entity1 , 1.50 in @entity1 ); in @entity1 only, salivary glands (RR, 2.96), prostate (RR, 1.28), testis (RR, 12.7), urinary bladder (RR, 1.41), and @entity1778 (RR, 1.37); and in @entity1 only, breast (RR, 1.34). All-cause mortality was slightly increased (adjusted @entity1 's RR, 1.03 [95% CI, 1.00-1.06]; @entity1 's RR, 1.04 [95% CI, 1.00-1.09]). CONCLUSIONS: @entity1 with a history of @entity1489 are at increased risk of @entity5 mortality. Although the biological mechanisms are unknown, a history of @entity1489 should increase the clinician's alertness for certain noncutaneous @entity5 as well as @entity320 .
